Dermatology Reports
12 | lebrikizumab for paediatric patients aged ≥6 months with moderate-to-severe ad: Phase 3 ADORABLE-1 WEEK-16 results
By Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica.
Abstract
Atopic dermatitis (AD) is the most prevalent chronic inflammatory skin condition impacting 15—20% of children globally, with limited treatment options. Lebrikizumab (LEB) inhibits interleukin (IL)-13, a key driver of AD, and is approved for patients (pts) ≥12 years (y), ≥40kg with moderate-to-severe (mod-sev) AD inadequately treated with topicals. The ADorable 1 double-blind phase 3 study (NCT05559359) evaluated 16 week (W) efficacy and safety of LEB and topical corticosteroids (TCS) vs placebo (PBO) and TCS in pts aged 6 months (m) to
Keywords
- Dermatology and Skin Diseases
- lebrikizumab
- atopic dermatitis
- pediatric patients
- topical corticosteroids
- moderate-to-severe atopic dermatitis
- treatment efficacy and safety
- Open access
Source
Published in Dermatology Reports. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.